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Background: The risk of prostate cancer-specific mortality (PCSM) following a diagnosis of prostate cancer may
improve after patients have survived a number of years after diagnosis. We sought to determine long-term
conditional PCSM for patients with stage T4, N1, or M1 prostate cancer.
Methods: We identified 66,817 patients diagnosed with stage IV (T4N0M0, N1M0, or M1) prostate cancer between
1973 and 2011 using the Surveillance, Epidemiology, and End Results (SEER) database. Conditional five-year PCSM
was evaluated for each group of patients at 5, 10, and 15 years of survival according to the Fine & Gray model for
competing risks after adjusting for tumor grade, age, income level, and marital status. Race-stratified analyses were
also performed.
Results: There were 13,345 patients with T4 disease, 12,450 patients with N1 disease, and 41,022 patients with M1
disease. Median follow-up among survivors in the three groups was 123 months (range: 0–382 months), 61 months
(range: 0–410 months), and 30 months (range: 0–370 months), respectively. Conditional PCSM improved in all three
groups over time. Among patients with T4 disease, 5-year PCSM improved from 13.9 % at diagnosis to 11.2, 8.1, and
6.5 % conditioned on 5, 10, or 15 years of survival, respectively (p < 0.001 in all cases). In patients with N1 disease, 5-year
PCSM increased within the first five years and decreased thereafter, from 18.9 % at diagnosis to 21.4 % (p < 0.001), 17.6 %
(p = 0.055), and 13.8 % (p < 0.001), respectively. In patients with metastatic disease, 5-year PCSM improved from 57.2 % at
diagnosis to 41.1, 28.8, and 20.8 %, respectively (p < 0.001). White race was associated with a greater increase in
conditional survival compared to non-white race among those with T4 or N1 disease.
Conclusions: While patients with T4, N1, or M1 prostate cancer are never “cured,” their odds of cancer-specific survival
increase substantially after they have survived for 5 or more years. Physicians who take care of patients with prostate
cancer can use this data to guide follow-up decisions and to counsel newly diagnosed patients and survivors regarding
their long-term prognosis.
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Stage IV prostate cancer, consisting of stage T4 (invasion
of adjacent organs), N1 (regional nodal spread), or M1
(metastatic spread) disease [1], is a relatively rare diag-
nosis, accounting for approximately 5 % of prostate can-
cer diagnoses [2]. When a patient is diagnosed with such
unfavorable cancer, he may appropriately ask about his* Correspondence: pnguyen@LROC.harvard.edu
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creativecommons.org/publicdomain/zero/1.0/prognosis, which depends on many factors including his
specific tumor status, ability to tolerate cancer therapy,
and his competing health risks. One complicating factor
is that most cancer prognostic information is reported
from the time of diagnosis and may overestimate the risk
of mortality for the patient who has already survived
their disease for some time [3]. It can therefore be chal-
lenging, but important, to determine a patient’s changing
prognosis as he lives years past his diagnosis. Com-
pounding this challenge in patients with T4, N1, or M1
prostate cancer is that due to their relative rarity, somess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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when counseling patients about their long-term prognosis.
Some data suggests that patients with T4, N1, or M1
disease are unique in the degree to which prognosis im-
proves as patients survive their disease [4]. It is likely
that in each of these heterogeneous groups, patients with
worse disease die more quickly, such that the cancer-
specific survival for the remainder of the patients is rela-
tively better and therefore captured by the conditional
survival at 5–15 years following diagnosis. Most studies
on conditional mortality after a prostate cancer diagnosis
to-date have focused on either localized or distant disease,
with no studies to our knowledge specifically examining
the conditional mortality of patients with T4 or N1 disease
[5–8]. In addition, studies have usually reported mortality
conditioned on 5 years or occasionally 10 years of survival,
but not as long as 15 years [9]. In this study, we determine
the prognosis of prostate cancer patients with T4, N1,
or M1 disease conditioned on up to 15 years of sur-
vival. As a secondary aim, we also determine the inter-
action between race and conditional mortality to study
the possibility that barriers to long-term cancer follow-
up among minorities might affect how long-term prog-
nosis changes over time [10].
Methods
Patient population
The Surveillance, Epidemiology, and End Results (SEER)
database collects cancer diagnostic, treatment, and sur-
vival data from 18 SEER registries, accounting for ap-
proximately 28.0 % of the US population [11]. We used
the SEER*Stat 8.1.5 software to extract cases from the
SEER database. This study was approved by the Institutional
Review Board at the Dana-Farber Cancer Institute.
Patients were included if they were diagnosed with stage
T4N0M0, N1M0, or M1 prostate cancer between 1973
and 2011. In total, this approach identified 66,817 men.
We collected information from SEER on tumor character-
istics, including clinical staging information and grade.
We also extracted patient characteristics, including sur-
vival information, age at diagnosis, marital status at diag-
nosis, race, median family income in the county of
diagnosis, cause of death, and length of survival.
Statistical analysis
Stata/MP 13.1 was used for all statistical analyses. Pa-
tient demographic data were summarized for patients
with T4, N1, or M1 disease. Prostate cancer-specific
mortality was estimated using the Fine & Gray model
[12] for competing risks, adjusting for marital status,
race, age, median family income in the county of
diagnosis, and tumor grade. Conditional mortality at
time T was determined by identifying patients who
survived for S > Tmonths and generating a newsurvival variable S’ = S - T. Survival analysis was then
performed on patients who survived past time S using
S’ as the survival variable and compared to the gen-
eral cohort using S as the survival variable. This pro-
cedure was repeated for T = 5, 10, or 15 years. We
also analyzed subgroups of patients with M1 disease
based on whether they had M1a disease (distant
lymph node involvement), M1b disease (bone involve-
ment), or M1c disease (other site involvement with or
without bone involvement) [1]. Analyses were also re-
peated following stratification by race (white versus
non-white). Interaction analysis was performed as has
previously been reported [13], namely by modeling
the effect of a new variable race*SurvivalT, where
SurvivalT represents whether or not a patient sur-
vived past time T. P-values were reported as statisti-
cally significant if less than α = 0.05 after correction
for multiple comparisons, when applicable [14]. Spe-
cifically, we used α = 0.05/3 = 0.0167 for the calcula-
tions of 5-year PCSM conditioned on 5, 10, or
15 years of survival.
Results
Patient characteristics
There were 13,345 patients with T4 disease, 12,450 pa-
tients with N1 disease, and 41,022 patients with M1 dis-
ease. Median follow-up among survivors in the three
groups was 123 months (range: 0–382 months), 61 months
(range: 0–410 months), and 30 months (range: 0–370
months), respectively. Other baseline characteristics of the
three cohorts and of those who survived for 5, 10, or
15 years are represented in Table 1.
Conditional mortality improves over time among patients
with T4, N1, or M1 prostate cancer
Conditional adjusted prostate cancer-specific mortality im-
proved among patients with T4, N1, or M1 disease over
time (Table 2 and Fig. 1). Among patients with T4 disease,
5-year PCSM improved from 13.9 % at diagnosis to 11.2,
8.1, and 6.5 % conditioned on 5, 10, or 15 years of survival,
respectively (p < 0.001 in all cases). In patients with N1 dis-
ease, 5-year PCSM slightly worsened within the first five
years, from 18.9 % at diagnosis to 21.4 % conditioned on
5 years of survival (p < 0.001), but then declined to 17.6 %
(p = 0.055) and 13.8 % (p < 0.001) conditioned on 10 and
15 years of survival, respectively.
In patients with metastatic disease, 5-year PCSM
improved from 57.2 % at diagnosis to 41.1, 28.8, and
20.8 % conditioned on 5, 10, and 15 years of sur-
vival, respectively (p < 0.001 in all cases). In subgroup
analyses (see Table 3 and Fig. 2), patients with M1a
disease (N = 3,950) had improved 5-year PCSM from
55.0 % at diagnosis to 42.4, 34.4, and 17.0 % at 5, 10,
and 15 years of survival, respectively (p < 0.005 in all
Table 1 Characteristics among patients with T4, N1, or M1 disease at diagnosis and at 5, 10, and 15 years of survival
T4
At diagnosis 5 years 10 years 15 years
N 13,345 7,921 4,839 2,743
% White 81.1 % 82.1 % 83.7 % 86.3 %
Median age at diagnosis 68 67 66 65
% Married 76.8 % 81.7 % 84.1 % 86.6 %
Median family income in county of residence $53,880 $54,020 $54,470 $55,470
% Low-grade (Gleason score less than 7) 51.0 % 65.4 % 73.9 % 78.1 %
N1
At diagnosis 5 years 10 years 15 years
N 12,450 6,791 3,069 1,196
% White 83.4 % 84.1 % 85.2 % 86.2 %
Median age at diagnosis 65 65 65 64
% Married 78.5 % 81.5 % 84.5 % 87.0 %
Median family income in county of residence $53,440 $53,880 $54,470 $56,490
% Low-grade (Gleason score less than 7) 33.3 % 46.1 % 57.4 % 62.0 %
M1
At diagnosis 5 years 10 years 15 years
N 41,022 7,514 1,960 525
% White 75.6 % 75.2 % 74.0 % 77.3 %
Median age at diagnosis 72 70 69 67
% Married 65.5 % 73.3 % 77.9 % 83.2 %
Median family income in county of residence $53,440 $54,020 $56,960 $58,140
% Low-grade (Gleason score less than 7) 28.7 % 46.8 % 61.1 % 66.5 %
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(N = 14,413), 5-year PCSM improved from 59.7 % at
diagnosis to 49.1, 36.0, and 29.7 % at 5, 10, and
15 years of survival (p < 0.001 in all cases). For the
subgroup of patients with M1c disease (N = 4,130), 5-
year PCSM improved from 62.6 % at diagnosis to
46.5 % and 39.6 % at 5 and 10 years of survival, re-
spectively (p < 0.005 in both cases), with no significant
difference at 15 years of survival (48.7 %, p = 0.221).
White patients derive a larger conditional mortality
benefit than non-white patients
In order to determine whether race interacted with
survival, we repeated our initial analyses after stratify-
ing by race and by modeling an interaction term.Table 2 Five-year adjusted conditional PCSM for patients with
T4, N1, or M1 disease
5-year PCSM T4 N1 M1
at diagnosis 13.9 % (ref) 18.9 % (ref) 57.2 % (ref)
after 5 years 11.2 % (p < 0.001) 21.4 % (p < 0.001) 41.4 % (p < 0.001)
after 10 years 8.1 % (p < 0.001) 17.6 % (p = 0.055) 28.8 % (p < 0.001)
after 15 years 6.5 % (p < 0.001) 13.8 % (p < 0.001) 20.8 % (p < 0.001)Among patients with M1 disease, conditional mortal-
ity was similar between white and non-white patients
(data not shown). However, among patients with N1
disease, non-white patients did not have a significant
reduction in conditional mortality at 5, 10, or 15 years
of survival compared to diagnosis (adjusted HR = 1.16
[p = 0.051], AHR = 1.04 [p = 0.686], and AHR = 0.881
[p = 0.593], respectively), while white patients had
similar mortality as the overall cohort, with adjusted
hazard ratios of 1.10 (p < 0.001), 0.898 (p = 0.022), and
0.712 (p < 0.001), respectively. While non-white pa-
tients with T4 disease had improved 5-year PCSM
after having survived 5, 10, or 15 years, their im-
provements were 20-39 % smaller than those of white
patients (p < 0.05 by interaction analysis).
Discussion
Among patients with T4, N1, or M1 prostate cancer, we
found that 5-year prostate cancer-specific mortality
(PCSM) generally improved among all three groups con-
ditioned on 5, 10, or 15 years of survival (with the excep-
tion of patients with N1 disease conditioned on 5 years of
survival), even after adjusting for patient-specific factors
like tumor grade, age, marital status, county-wide median
Fig. 1 Five-year PCSM among patients with T4 (a), N1 (b), or M1 (c) prostate cancer at diagnosis and conditioned on 5, 10, or 15 years of survival
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tionship was stronger in white patients than among non-
white patients with T4 or N1 disease.
These data may be of great interest to physicians and
patients. Our survival analyses imply that cancer-specific
mortality is not static after diagnosis with advanced
prostate cancer. While it may not be appropriate to labelpatients with advanced-stage prostate cancer as “cured”
after surviving for several years, many of these patients
are at significantly reduced likelihood of cancer-specific
death the longer they survive. Physicians should use re-
sults to better counsel patients and provide appropriate
follow-up and surveillance. For example, we found that
cancer-specific mortality drops sharply among patients
Table 3 Five-year adjusted conditional PCSM for patients with
M1a, M1b or M1c disease
5-year PCSM M1a M1b M1c
at diagnosis 55.0 % (ref) 59.7 % (ref) 62.6 % (ref)
after 5 years 42.4 % (p < 0.005) 49.1 % (p < 0.001) 46.5 % (p < 0.005)
after 10 years 34.4 % (p < 0.005) 36.0 % (p = 0.055) 39.6 % (p < 0.005)
after 15 years 17.0 % (p < 0.005) 29.7 % (p < 0.001) 48.7 % (p = 0.221)
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Therefore, it would be appropriate for clinicians to in-
crease the time between follow-up appointments, im-
aging, and laboratory tests once patients survive to
5 years. On the other hand, we found that patients with
N1 disease did not have a reduction in PCSM until
10 years. Therefore, physicians should monitor the N1
patient who has survived for 5 years just as closely as
they would monitor the newly diagnosed one.
Patients can also use this data to better understand
how their long-term prognosis changes over time. Most
cancer-specific mortality data is reported from diagnosis.
Therefore, it can be difficult to re-assess prognosis for
the fortunate patient who is able to survive 5, 10, or
even 15 years after diagnosis. Our data can help patients
understand their changing risk of PCSM as time passes.
For example, a patient newly diagnosed with metastatic
prostate cancer would likely be counseled that their risk
of dying within five years is 50 % or more [15]. In con-
trast, based on our data, one who has survived for 5 years
already should be counseled that their risk of dying in
the next five years is much lower. Counseling patients
about their improving risk of mortality over time may
have important psychological and emotional benefits for
patients and their families [16, 17].
In addition to our findings that conditional survival
improved among all three groups of patients, our sec-
ondary analyses may point to racial disparities in
long-term prostate cancer care. We found that among
patients with T4 disease, non-white patients had
smaller improvements in survival than white patients;
among those with N1 disease, non-white patients had
no improvement at all. While others have shown that
minorities are at higher risk of cancer-specific mortal-
ity [18], our results show that the differences may
grow proportionally larger as time goes on. These dif-
ferences may be due to racial disparities in follow-up
surveillance following initial cancer treatment and dif-
ferences in the eventual receipt of salvage therapy. Minor-
ities have previously been shown to report more barriers
to follow-up care after completing cancer treatment [10].
Our data suggest that these differences in follow-up may
translate to smaller reductions in cancer-specific mortality
over time, resulting in relatively more cancer-specific
death among non-white patients compared to whitepatients. Physicians should therefore pay special attention
to minority patients with advanced prostate cancer to
make sure they receive excellent long-term follow-up and
surveillance in order to help reverse this cause of
increased cancer-specific mortality.
To our knowledge, other studies examining condi-
tional survival from prostate cancer have not specific-
ally examined patients with T4 or N1 disease, two
important subsets of patients with whom some clini-
cians may have limited experience due to their rela-
tive rarity [4–7, 9]. Some authors have reported the
conditional outcomes of all stage IV patients together
[4, 8], but because the subsets of stage IV patients
have very heterogeneous outcomes [15] the data pre-
sented here may be more clinically applicable since we
have separately considered T4, N1, and M1 disease. One
study in patients with pathologic N1 disease demonstrated
that conditional freedom from biochemical recurrence rap-
idly improves within the first five years after diagnosis but
did not report mortality data [19]. In addition, we calcu-
lated 5-year PCSM conditioned on up to 15 years of sur-
vival, whereas most previous studies have stopped at
5 years of survival. Our results for the subset of patients
with M1 disease are consistent with the results of similar
studies [6, 8, 9], with some variation in the estimates of
PCSM referable to differences in cohort selection (e.g.
country of study) and statistical techniques (e.g. use of Fine
& Gray’s model with adjustment for patient demographic
factors in our study versus calculation of excess mortality
or use of life tables in other studies). Our subgroup ana-
lyses of patients with M1a, M1b, or M1c disease showed
moderate heterogeneity in the conditional mortality esti-
mates. These results are consistent with the work others
showing somewhat differing survival outcomes among
these three groups [20, 21], with M1c conferring the worst
prognosis overall and the smallest improvements in condi-
tional mortality out of the three subgroups.
Despite our sample size, our study has some limita-
tions. First, the SEER database does not contain data
about disease recurrence or receipt of salvage therapy.
Therefore, we were not able to analyze these import-
ant secondary outcomes. Second, the SEER database
has previously been reported to have coding errors in
cancer stage [22], so we may have erroneously in-
cluded or excluded some patients in our study. While
this may reduce the reliability of our results, coding
errors are likely to be random and therefore not likely
to systematically bias our findings. Third, our cohort
includes patients over a very long time period. Im-
provements in cancer care and disease surveillance
(e.g. more sensitive prostate-specific antigen and im-
proved imaging) over the past decades could lead to our
data overestimating the PCSM compared to a modern
patient’s risk.
Fig. 2 Five-year PCSM among patients with M1a (a), M1b (b), or M2c (c) prostate cancer at diagnosis and conditioned on 5, 10, or 15 years
of survival
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In order to better understand how the cancer-specific
mortality risk of advanced prostate cancer changes over
time, we studied the conditional mortality of patients
with stage T4, N1, or M1 prostate cancer. We found thatin all three groups (T4, N1, and M1), cancer-specific
mortality generally improved after survival to 5, 10, or
15 years. Among those with T4 or N1 disease, non-white
patients had smaller improvements compared to white
patients or no improvement at all. Our results should be
Muralidhar et al. Radiation Oncology  (2015) 10:155 Page 7 of 7used to counsel prostate cancer survivors on their chan-
ging risk profile and to tailor follow-up and cancer sur-
veillance over time. In addition, physicians should pay
special attention to minority patients, as they may be at
risk for relatively poor conditional mortality, possibly
due to worse long-term follow-up.
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